PDF(Pubmed)
Abstract：
In this issue honoring the contributions of Greg Lemke, the Earp and Graham lab teams discuss several threads in the discovery, action, signaling, and translational/clinical potential of MERTK, originally called c-mer, a member of the TYRO3, AXL, and MERTK (TAM) family of receptor tyrosine kinases. The 30-year history of the TAM RTK family began slowly as all three members were orphan RTKs without known ligands and/or functions when discovered by three distinct alternate molecular cloning strategies in the pre-genome sequencing era. The pace of understanding their physiologic and pathophysiologic roles has accelerated over the last decade. The activation of ligands bridging externalized phosphatidylserine (PtdSer) has placed these RTKs in a myriad of processes including neurodevelopment, cancer, and autoimmunity. The field is ripe for further advancement and this article hopefully sets the stage for further understanding and therapeutic intervention. Our review will focus on progress made through the collaborations of the Earp and Graham labs over the past 30 years.
摘要：
本期纪念格雷格·莱姆克的贡献,厄普和格雷厄姆实验室团队讨论了这个发现的几个线索，行动,信令,和MERTK的转化/临床潜力，最初称为c-mer，TYRO3，AXL的成员，和受体酪氨酸激酶的MERTK(TAM)家族。TAMRTK家族的30年历史开始缓慢，因为所有三个成员都是孤儿RTK，在基因组前测序时代通过三种不同的替代分子克隆策略发现时，没有已知的配体和/或功能。在过去的十年中，了解其生理和病理生理作用的步伐加快了。配体桥接外化磷脂酰丝氨酸（PtdSer）的激活使这些RTK处于包括神经发育在内的无数过程中，癌症,和自身免疫。该领域的进一步发展已经成熟，本文希望为进一步的理解和治疗干预奠定基础。我们的审查将集中在Earp和Graham实验室在过去30年的合作中取得的进展。
